New York, May 21, 2026, 17:05 (EDT)
Abivax SA’s Nasdaq-listed shares climbed on Thursday, putting a fresh SEC filing back in focus as investors waited for late-quarter data on its lead ulcerative colitis drug.
The French biotech’s American Depositary Shares, or ADSs — U.S.-traded receipts for foreign shares — were recently quoted at $124.03, up 3.5%, with volume of about 1.65 million shares. The stock traded between $117.23 and $126.37 during the session.
Why it matters now is simple. Abivax expects late-Q2 topline results from the 44-week maintenance portion of its Phase 3 ABTECT trial of obefazimod in moderate-to-severe ulcerative colitis. Phase 3 is late-stage testing generally used to support regulatory filings. The company has said it plans a U.S. filing later in 2026 if the data support it.
In Paris, Abivax ordinary shares closed at 105.10 euros, up 2.14%, after trading as high as 105.30 euros. The Paris line remains below its 52-week high of 132 euros, but far above the low of 5 euros.
The May 20 Form 6-K showed shareholders approved all items at the May 11 annual meeting, with an 86.06% participation rate. The approvals included capital-raising mandates and a U.S. at-the-market, or ATM, program — a facility that can let a company sell shares into the market over time — which passed with 78.20% of votes for and 21.80% against.
That vote lands after Abivax moved earlier this month to clean up part of its capital structure. On May 5, the company said it would repurchase royalty certificates for $90 million, half in cash and half through 403,347 ADSs priced at $111.57 each. Chief Financial Officer Didier Blondel said, “Strengthening our balance sheet remains a core priority.” Abivax
Abivax said the royalty deal would not change its projected cash runway into the fourth quarter of 2027. The company also warned that future share sales could weigh on the ADS price and that new capital could dilute shareholders.
The stock is no longer a small, ignored biotech name. Abivax has traded on Euronext Paris since 2015 and on the Nasdaq Global Market since October 2023; it was also added to the Nasdaq Biotechnology Index effective before the Dec. 22, 2025 market open.
Competitive pressure is real. Bigger drugmakers including Eli Lilly, Pfizer and Roche have been active in inflammatory-disease assets, while analysts have focused on whether obefazimod can stand out as an oral therapy in inflammatory bowel disease. Leerink Partners analyst Thomas J. Smith wrote last year that obefazimod had a “compelling balance of efficacy, safety and convenience,” according to BioPharma Dive. BioPharma Dive
Takeover chatter has also shadowed the stock. In January, Chief Executive Marc de Garidel dismissed reports linking Abivax to Eli Lilly as “noise” and said, “our duty is not to be distracted.” Reuters reported then that analysts at Morgan Stanley, Piper Sandler and Truist had raised targets to $140-$145, citing obefazimod’s commercial potential and Abivax’s appeal as a possible acquisition target. Reuters
But the setup cuts both ways. A weak or mixed maintenance readout would hit the central reason investors own the shares, and even good data would still need regulatory review. The ATM approval also gives the board more flexibility, but for shareholders it carries the familiar biotech risk: more stock can mean dilution, or a lower claim on future upside per share.
The next scheduled corporate marker on Abivax’s investor calendar is Q1 2026 financial results, listed for May 25. Until then, the tape is likely to stay driven less by quarterly numbers and more by positioning ahead of the obefazimod maintenance data.
